These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 26536114)

  • 1. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus.
    Lehar SM; Pillow T; Xu M; Staben L; Kajihara KK; Vandlen R; DePalatis L; Raab H; Hazenbos WL; Morisaki JH; Kim J; Park S; Darwish M; Lee BC; Hernandez H; Loyet KM; Lupardus P; Fong R; Yan D; Chalouni C; Luis E; Khalfin Y; Plise E; Cheong J; Lyssikatos JP; Strandh M; Koefoed K; Andersen PS; Flygare JA; Wah Tan M; Brown EJ; Mariathasan S
    Nature; 2015 Nov; 527(7578):323-8. PubMed ID: 26536114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial drugs: Antibody-antibiotic conjugate tracks down hidden S. aureus.
    Bray N
    Nat Rev Drug Discov; 2016 Jan; 15(1):18. PubMed ID: 26718281
    [No Abstract]   [Full Text] [Related]  

  • 3. Antibiotics: Homed to the hideout.
    Hardt WD
    Nature; 2015 Nov; 527(7578):309-10. PubMed ID: 26536107
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibody-antibiotic conjugate targeted therapy for orthopedic implant-associated intracellular S. aureus infections.
    Qin L; Hu N; Zhang Y; Yang J; Zhao L; Zhang X; Yang Y; Zhang J; Zou Y; Wei K; Zhao C; Li Y; Zeng H; Huang W; Zou Q
    J Adv Res; 2024 Nov; 65():239-255. PubMed ID: 38048846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
    Smith TL; Pearson ML; Wilcox KR; Cruz C; Lancaster MV; Robinson-Dunn B; Tenover FC; Zervos MJ; Band JD; White E; Jarvis WR
    N Engl J Med; 1999 Feb; 340(7):493-501. PubMed ID: 10021469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia.
    Holmes NE; Turnidge JD; Munckhof WJ; Robinson JO; Korman TM; O'Sullivan MV; Anderson TL; Roberts SA; Warren SJ; Gao W; Johnson PD; Howden BP
    Clin Microbiol Infect; 2013 Dec; 19(12):1163-8. PubMed ID: 23441652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained activity of novel THIOMAB antibody-antibiotic conjugate against Staphylococcus aureus in a mouse model: Longitudinal pharmacodynamic assessment by bioluminescence imaging.
    Zhou C; Cai H; Baruch A; Lewin-Koh N; Yang M; Guo F; Xu D; Deng R; Hazenbos W; Kamath AV
    PLoS One; 2019; 14(10):e0224096. PubMed ID: 31661493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel antibody-antibiotic conjugate using KRM-1657 as payload eliminates intracellular MRSA in vitro and in vivo.
    Fan S; Bai Y; Li Q; Liu L; Wang Y; Xie F; Dong Y; Wang Z; Lv K; Zhu H; Bi H; Zhou X
    Bioorg Chem; 2024 Sep; 150():107532. PubMed ID: 38852312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.
    Charles PG; Ward PB; Johnson PD; Howden BP; Grayson ML
    Clin Infect Dis; 2004 Feb; 38(3):448-51. PubMed ID: 14727222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of pharmacodynamic target attainment with vancomycin treatment of bacteremia due to Staphylococcus aureus methicillin resistant].
    Lepe JA; Gil-Navarro MV; Santos-Rubio MD; Bautista J; Aznar J
    Rev Esp Quimioter; 2010 Mar; 23(1):43-7. PubMed ID: 20232023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
    Walraven CJ; North MS; Marr-Lyon L; Deming P; Sakoulas G; Mercier RC
    J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin.
    Price J; Atkinson S; Llewelyn M; Paul J
    Clin Infect Dis; 2009 Apr; 48(7):997-8. PubMed ID: 19260820
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia.
    Khatib R; Saeed S; Sharma M; Riederer K; Fakih MG; Johnson LB
    Eur J Clin Microbiol Infect Dis; 2006 Mar; 25(3):181-5. PubMed ID: 16505987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Bennett JW; Murray CK; Holmes RL; Patterson JE; Jorgensen JH
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia.
    Barber KE; Rybak MJ; Sakoulas G
    J Antimicrob Chemother; 2015 Jan; 70(1):311-3. PubMed ID: 25125677
    [No Abstract]   [Full Text] [Related]  

  • 16. Audit of the management of Staphylococcus aureus bloodstream infection: gaps to be plugged.
    Barry A; McNicholas S; Smyth E; Humphreys H; Fitzpatrick F
    J Hosp Infect; 2010 Nov; 76(3):272-3. PubMed ID: 20435374
    [No Abstract]   [Full Text] [Related]  

  • 17. Influence of early daptomycin therapy on treatment outcome of meticillin-resistant Staphylococcus aureus bacteraemia with high vancomycin minimum inhibitory concentrations.
    Cheng CW; Hsu PC; Yang CC; Chang HJ; Siu LK; Wu TL; Huang CT; Lee MH
    Int J Antimicrob Agents; 2013 Mar; 41(3):293-4. PubMed ID: 23312599
    [No Abstract]   [Full Text] [Related]  

  • 18. More accurate measurement of vancomycin minimum inhibitory concentration indicates poor outcomes in meticillin-resistant Staphylococcus aureus bacteraemia.
    Shoji H; Maeda M; Shirakura T; Takuma T; Ugajin K; Fukuchi K; Ishino K; Niki Y
    Int J Antimicrob Agents; 2015 Nov; 46(5):532-7. PubMed ID: 26364848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.
    Gomes DM; Ward KE; LaPlante KL
    Pharmacotherapy; 2015 Apr; 35(4):424-32. PubMed ID: 25884530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
    Sakoulas G; Moellering RC
    Clin Infect Dis; 2008 Jun; 46 Suppl 5():S360-7. PubMed ID: 18462091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.